<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Approach to the patient following treatment for breast cancer</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Approach to the patient following treatment for breast cancer</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Approach to the patient following treatment for breast cancer</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kathryn J Ruddy, MD, MPH</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Ann H Partridge, MD, MPH</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Larissa Nekhlyudov, MD, MPH</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Harold J Burstein, MD, PhD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Gary J Whitman, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sadhna R Vora, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Dec 19, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H346411016"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>According to statistics from the International Agency for Research on Cancer (IARC), there are approximately 44 million people living with cancer worldwide [<a href="#rid1">1</a>]. In the United States, the five-year survival rate for female breast cancer is approximately 90 percent [<a href="#rid2">2</a>]. Additionally, although the vast majority of breast cancer survivors are women, approximately 2500 men are diagnosed with breast cancer annually in the United States alone, and most will achieve long-term disease-free survival [<a href="#rid3">3</a>]. (See  <a class="medical medical_review" href="/d/html/779.html" rel="external">"Breast cancer in men"</a>.)</p><p>Patients who are living for decades beyond cancer experience the normal issues of aging, which are often compounded by the long-term effects of having had cancer and cancer therapy. These patients are at risk for a breast cancer recurrence (which is most common in the first five years but may occur even decades following treatment), a new primary breast cancer, other cancers, and short-term and long-term adverse effects of treatment. Additional issues for cancer survivors relate to psychologic, genetic, reproductive, social, and employment concerns.</p><p>Unfortunately, there is a lack of clear evidence surrounding many issues for what constitutes best practices in caring for patients with a history of cancer, and this contributes to wide variation in care [<a href="#rid4">4</a>]. Recommendations for post-treatment surveillance after primary therapy of breast cancer will be reviewed here. Detailed discussions of prognosis, the patterns of relapse (ie, locoregional recurrence, second primary breast tumor, metastatic disease), and long-term complications of breast cancer therapy are presented separately. (See  <a class="medical medical_review" href="/d/html/737.html" rel="external">"Overview of the treatment of newly diagnosed, invasive, non-metastatic breast cancer", section on 'Prognosis'</a> and  <a class="medical medical_review" href="/d/html/782.html" rel="external">"Prognostic and predictive factors in early, non-metastatic breast cancer"</a> and  <a class="medical medical_review" href="/d/html/754.html" rel="external">"Overview of long-term complications of therapy in breast cancer survivors and patterns of relapse"</a>.)</p><p>A general overview of cancer survivorship is covered separately. (See  <a class="medical medical_review" href="/d/html/16613.html" rel="external">"Overview of cancer survivorship care for primary care and oncology providers"</a>.)</p><p class="headingAnchor" id="H541710487"><span class="h1">DEFINING A CANCER SURVIVOR</span><span class="headingEndMark"> — </span>There are many definitions and phases of cancer survivorship. We define a cancer survivor as any person with cancer, starting from the moment of diagnosis. This is consistent with definitions from the National Coalition for Cancer Survivorship [<a href="#rid5">5</a>] and the National Cancer Institute [<a href="#rid6">6</a>]. By this definition, there are more than four million breast cancer survivors in the United States, including over 150,000 living with overt metastatic disease [<a href="#rid7">7</a>].</p><p>This overview addresses breast cancer survivors who have completed initial treatment for breast cancer (ie, surgery, chemotherapy, and/or radiation therapy) and who are without evidence of disease.</p><p class="headingAnchor" id="H346411030"><span class="h1">GUIDELINES FOR POST-TREATMENT FOLLOW-UP</span><span class="headingEndMark"> — </span>Guidelines from the American Society of Clinical Oncology (ASCO) suggest that patients with early-stage breast cancer (tumor &lt;5 cm and fewer than four positive nodes) may follow up exclusively with a primary care provider (PCP); for patients and clinicians who agree with this plan, care may be transferred approximately one year after diagnosis [<a href="#rid8">8</a>]. In such cases, both the patient and the PCP should be advised of the appropriate follow-up and management strategy.</p><p>Additional guidelines for post-treatment follow-up were made by the Institute of Medicine; these are discussed separately. (See  <a class="medical medical_review" href="/d/html/16613.html" rel="external">"Overview of cancer survivorship care for primary care and oncology providers", section on 'Components of posttreatment follow-up'</a>.)</p><p>Prognosis of nonmetastatic breast cancer is discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/737.html" rel="external">"Overview of the treatment of newly diagnosed, invasive, non-metastatic breast cancer", section on 'Prognosis'</a> and  <a class="medical medical_review" href="/d/html/782.html" rel="external">"Prognostic and predictive factors in early, non-metastatic breast cancer"</a>.)</p><p>Data are sparse to inform optimal follow-up of male breast cancer survivors; recommendations for women are usually applied to men, with modification as appropriate.</p><p>For patients receiving adjuvant hormonal therapy, informed decisions regarding long-term options may necessitate periodic referral for oncology assessment since treatment strategies are evolving over time. Furthermore, input from an oncology specialist is warranted if there is suspicion or evidence of disease recurrence, or if questions arise regarding the safety of certain interventions (eg, vaginal estrogen in a patient who has atrophic vaginitis).</p><p>Breast cancer survivors should receive ongoing age-appropriate screening studies and preventive care, consistent with recommendations for the general population, for conditions other than those related to breast cancer and its treatment. (See  <a class="medical medical_review" href="/d/html/97819.html" rel="external">"Overview of preventive care in adults"</a>.)</p><p class="headingAnchor" id="H12559591"><span class="h1">COMPONENTS OF FOLLOW-UP</span><span class="headingEndMark"> — </span>Components of follow-up are discussed below and in the algorithm  (<a class="graphic graphic_algorithm graphicRef119034" href="/d/graphic/119034.html" rel="external">algorithm 1</a>).</p><p class="headingAnchor" id="H541711608"><span class="h2">History and physical examination</span><span class="headingEndMark"> — </span>History and physical examination have been the principal means of detecting a breast cancer recurrence [<a href="#rid9">9-11</a>]. We suggest that patients be seen every three to six months during the first three years after primary therapy, every 6 to 12 months for the next two years, and then annually  (<a class="graphic graphic_table graphicRef61501" href="/d/graphic/61501.html" rel="external">table 1</a>), consistent with the American Society of Clinical Oncology (ASCO) 2015 guidelines [<a href="#rid12">12</a>]. However, this schedule is arbitrary; no studies have evaluated the benefit of less frequent clinical visits in patients with low-risk disease or more frequent visits in those with higher-risk disease [<a href="#rid13">13</a>].</p><p class="headingAnchor" id="H541711675"><span class="h3">History</span><span class="headingEndMark"> — </span>In addition to the general components of a medical history, the breast cancer survivor should be screened for symptoms of local recurrence as well as metastatic disease. Patients should also be asked about their adherence to any adjuvant treatments that have been recommended. Any changes in the family history should be obtained, which may be important to discussions regarding genetic counseling. (See <a class="local">'Genetic counseling'</a> below.)</p><p>The history should include any interval changes in the patient's social environment (including partner status, life events, living arrangements, and occupational issues) that may have arisen since the end of treatment.</p><p>A review of systems should not only screen for metastatic disease but also may identify issues related to prior treatment. We suggest that the review of systems include the following [<a href="#rid14">14,15</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Constitutional symptoms</strong> – Anorexia, weight loss, malaise, fatigue, insomnia.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bone health</strong> – Presence of pain and its characteristics (ie, location, character of pain [dull or aching], chronic or intermittent, associated symptoms, exacerbating factors, and what provides relief).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pulmonary symptoms</strong> – Persistent cough or dyspnea (at rest or with exertion).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Neurologic symptoms</strong> – Headache, nausea, vomiting, confusion, weakness, numbness, or tingling.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Gastrointestinal symptoms</strong> – Right upper-quadrant pain, change in bowel habits, presence of bloody or tarry stools.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Genitourinary symptoms</strong> – Vaginal bleeding, pelvic pain, difficulty urinating.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Psychological symptoms</strong> – Depression, anxiety.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Reproductive/endocrine symptoms</strong> – Hot flashes, dyspareunia, vaginal dryness, sexual dysfunction, fertility concerns (in women with intact ovarian function).</p><p></p><p class="headingAnchor" id="H541711682"><span class="h3">Physical examination</span><span class="headingEndMark"> — </span>We suggest that a complete physical examination be performed at each visit, which is consistent with ASCO guidelines [<a href="#rid12">12</a>]. At a minimum, the examination should include [<a href="#rid14">14,15</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Examination of the breast, chest wall, and axilla</strong> – Thorough examination should be performed of the affected breast (if preserved) or the chest wall, the contralateral side, the bilateral axillary regions, and the supraclavicular fossas. For those patients who underwent breast-conserving treatment, providers should be comfortable examining the previously irradiated breast.</p><p></p><p class="bulletIndent1">The breast examination in patients who underwent adjuvant radiation therapy may not be helpful. In a review summarizing the results of seven randomized clinical trials, the sensitivity and specificity of physical examination ranged from 29 to 74 percent and from 17 to 30 percent, respectively [<a href="#rid16">16</a>]. (See  <a class="medical medical_review" href="/d/html/754.html" rel="external">"Overview of long-term complications of therapy in breast cancer survivors and patterns of relapse"</a>.)</p><p></p><p class="bulletIndent1">Diagrams of the affected breast, including postoperative and postradiotherapy changes, can be helpful in documenting and following the examination over time.</p><p></p><p class="bulletIndent1">Evidence of local recurrence includes newly discovered lumps (on the skin, within the breast, or the nodal regions). Other worrisome findings may include skin changes in the breast  (<a class="graphic graphic_table graphicRef80826" href="/d/graphic/80826.html" rel="external">table 2</a>). For women who have undergone mastectomy with or without breast reconstruction, the incision site and the surrounding skin of the chest wall should be examined visually and palpated for abnormalities.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Musculoskeletal examination</strong> – If lymphedema is suspected, examination of the arms should include circumferential measurement of the upper extremities bilaterally. (See  <a class="medical medical_review" href="/d/html/755.html" rel="external">"Clinical features and diagnosis of peripheral lymphedema"</a>.)</p><p></p><p class="bulletIndent1">In addition, palpation of the spine, sternum, ribs, and pelvis for bone tenderness should be routinely performed.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lung examination</strong> – Evaluation for breath sounds and percussion changes.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Abdominal examination</strong> – Evaluation for right upper quadrant tenderness and/or organomegaly.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cardiac examination</strong> – Evaluation for heart failure. (See  <a class="medical medical_review" href="/d/html/3485.html" rel="external">"Determining the etiology and severity of heart failure or cardiomyopathy", section on 'Physical examination'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Neurologic examination</strong> – Evaluation of balance, gait, and sensory and motor function. (See  <a class="medical medical_review" href="/d/html/5095.html" rel="external">"The detailed neurologic examination in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Gynecologic examination</strong> – Regular gynecologic follow-up should be performed for women who have not undergone total hysterectomy  (<a class="graphic graphic_table graphicRef61501" href="/d/graphic/61501.html" rel="external">table 1</a>) [<a href="#rid12">12</a>]. This is particularly important in women who are receiving <a class="drug drug_general" data-topicid="9972" href="/d/drug information/9972.html" rel="external">tamoxifen</a> because of the increased risk for endometrial tumors. (See  <a class="medical medical_review" href="/d/html/764.html" rel="external">"Managing the side effects of tamoxifen and aromatase inhibitors"</a>.)</p><p></p><p class="headingAnchor" id="H560048"><span class="h2">Breast imaging</span></p><p class="headingAnchor" id="H469430751"><span class="h3">Mammography</span><span class="headingEndMark"> — </span>The purpose of post-treatment mammographic surveillance is to detect ipsilateral local recurrences after breast-conserving therapy (BCT), which develops in up to 4 percent of women treated for early breast cancer [<a href="#rid17">17</a>]. In addition, mammography is performed as surveillance for a contralateral breast cancer. There is a lack of high-quality evidence to inform the optimal timing, methodology, and survival benefit of mammographic surveillance for detecting ipsilateral recurrence or a contralateral breast cancer [<a href="#rid18">18,19</a>]. For women in long-term follow-up, mammographic surveillance should be obtained annually.</p><p>We typically obtain a diagnostic mammogram annually for the first three to five years after diagnosis [<a href="#rid20">20</a>], and then switch to screening mammograms afterwards, although practice is variable across institutions. The rationale for diagnostic mammography during the first few years after diagnosis is that it detects recurrences and residual disease in a small percentage of cases and establishes a new baseline, as postsurgical and postradiation changes typically stabilize at three years. The views obtained in a diagnostic mammogram are tailored to evaluate a specific area, unlike in a screening mammogram. The difference between screening versus diagnostic mammography is discussed in more detail elsewhere. (See  <a class="medical medical_review" href="/d/html/7561.html" rel="external">"Breast imaging for cancer screening: Mammography and ultrasonography", section on 'Screening versus diagnostic mammography'</a>.)</p><p>Although the evidence is limited, surveillance mammography of residual breast tissue after BCT or unilateral mastectomy appears to be associated with a reduction in mortality among women of all ages [<a href="#rid19">19,21,22</a>]. This was illustrated best in a 2008 case-control study that compared mammographic utilization in women over 65 years who died or did not die of breast cancer and who lived at least 30 months following breast cancer diagnosis [<a href="#rid21">21</a>]. Women who had undergone a surveillance mammogram within one year were less likely to die of breast cancer (odds ratio [OR] 0.83, 95% CI 0.72-0.95).</p><p class="headingAnchor" id="H469430935"><span class="h4">Local recurrence</span><span class="headingEndMark"> — </span>There are no prospective trials that address the utility of mammography in the detection of local recurrence. Data from retrospective series suggest that mammography detects earlier lesions with a more favorable prognosis and that survival is improved in women whose lesions are detected mammographically as compared with those detected by other means [<a href="#rid23">23-25</a>]. However, other data suggest that mammographic screening in women with a personal history of breast cancer performs less well (lower sensitivity and slightly lower specificity) than in women without such a history [<a href="#rid26">26</a>]. In one study, women with a personal history of breast cancer had a higher rate of interval cancers compared with women without a history of breast cancer [<a href="#rid26">26</a>]. Fortunately, the majority of both screen-detected and interval cancers were early stage. (See  <a class="medical medical_review" href="/d/html/128420.html" rel="external">"Clinical manifestations and evaluation of locoregional recurrences of breast cancer"</a>.)</p><p class="headingAnchor" id="H469430942"><span class="h4">Contralateral breast cancer</span><span class="headingEndMark"> — </span>There are no randomized trials that address the role of mammography or its impact on survival in detecting contralateral breast cancers. However, recommendations for mammographic surveillance are based upon the benefits seen in the general population without a history of breast cancer. In general, breast cancer survivors are higher-risk women than the general population, and it would seem reasonable to infer that they derive as much or even more benefit from mammography of the contralateral breast. (See  <a class="medical medical_review" href="/d/html/7564.html" rel="external">"Screening for breast cancer: Strategies and recommendations"</a>.)</p><p>There is indirect evidence from retrospective series that supports a beneficial impact for mammography of the contralateral breast [<a href="#rid27">27-29</a>]. One study compared outcomes among a cohort of breast cancer survivors in which both physical examination and mammography were performed for post-treatment follow-up versus a separate cohort of women who were followed only by physical examination [<a href="#rid27">27</a>]. Although the frequency of contralateral breast cancer was similar in both groups, more recurrences were node-negative in the women with utilization of routine mammography (75 versus 57 percent, respectively). Furthermore, the contralateral tumors were more often smaller than 10 mm or in situ (noninvasive) (35 versus 7 percent, respectively) in women undergoing routine mammography.</p><p class="headingAnchor" id="H12559900"><span class="h3">Breast MRI</span><span class="headingEndMark"> — </span>Breast magnetic resonance imaging (MRI) is not routinely recommended for breast cancer survivors because of a lack of demonstrated benefit in this population. However, we obtain breast MRI for breast cancer survivors in the following circumstances:</p><p class="bulletIndent1"><span class="glyph">●</span>For women who have undergone breast conserving therapy who are at high risk for a second primary (&gt;20 percent lifetime risk), for example, based on a known breast cancer-associated gene mutation [<a href="#rid12">12,30-32</a>] (see  <a class="medical medical_review" href="/d/html/785.html" rel="external">"Overview of hereditary breast and ovarian cancer syndromes"</a>). This practice is extrapolated from the indications for breast MRI as a screening tool in high-risk women. (See  <a class="medical medical_review" href="/d/html/14972.html" rel="external">"MRI of the breast and emerging technologies", section on 'Screening high-risk women'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients suspected of a breast cancer recurrence (eg, on the basis of physical exam),</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>After breast conserving therapy when mammography, with or without breast ultrasound, is inconclusive [<a href="#rid33">33</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>After mastectomy, if ultrasound has been inconclusive.</p><p></p><p>Multiple studies have suggested no benefit for routine screening MRI in breast cancer survivors. In a 2012 systematic review that included 10 case series and 494 breast cancer survivors, the sensitivity and specificity of MRI to detect recurrent breast cancer was no better than mammography, historically [<a href="#rid34">34</a>]. In a meta-analysis of 16 studies in patients with prior breast cancer who underwent mastectomy (with or without reconstruction), MRI screening was associated with a cancer detection rate of 5.2 per 1000 screening exams (0.5 percent); however, the majority of detected cancers were palpable, arguing against routine MRI screening in the absence of physical exam findings [<a href="#rid35">35</a>].</p><p class="headingAnchor" id="H463691260"><span class="h3">Ultrasound</span><span class="headingEndMark"> — </span>Routine use of breast ultrasound (US) as part of surveillance is not recommended.</p><p>The addition of breast US to screening mammography was evaluated in a trial in which 2809 women with an elevated risk for breast cancer who were undergoing routine screening mammography were randomly assigned to mammography alone or with breast US [<a href="#rid36">36</a>]. Compared with mammography alone, ultrasound plus mammography increased the diagnostic yield (from 8 to 12 per 1000 women, 95% CI 1.1-7.2) but also increased the rate of false-positive results (4.4 versus 10.4 percent) and therefore lowered the positive predictive value.</p><p>In a meta-analysis among women with breast cancer who underwent mastectomy (with or without reconstruction), the cancer detection rate with routine ultrasonographic screening was just 2.7 per 1000 exams (0.3 percent), but the majority of detected cancers were palpable, arguing against ultrasound screening in patients lacking physical exam findings [<a href="#rid35">35</a>].</p><p class="headingAnchor" id="H469431146"><span class="h3">Surveillance of reconstructed breasts</span><span class="headingEndMark"> — </span>For women who have undergone mastectomy, surveillance is usually performed by physical examination. Routine mammographic imaging is technically limited in patients who have prosthetic implants and is generally not advocated. However, mammography is technically feasible following autogenous myocutaneous flap reconstruction, particularly following transverse rectus abdominis musculocutaneous (TRAM) or perforator flap reconstruction because abdominal adipose tissue forms the bulk of the reconstructed breast [<a href="#rid37">37</a>]. Although the available data are sparse, and there is no consensus on this issue, some institutions image TRAM-reconstructed breasts using mammography since even after mastectomy, some normal tissue may be left on the chest wall from which a new breast cancer may on occasion arise, although the value of this is unclear and likely limited. (See  <a class="medical medical_review" href="/d/html/801.html" rel="external">"Overview of breast reconstruction"</a>.)</p><p>The only place where cancer can occur is either right below the skin in the subcutaneous tissue or just over the pectoralis muscle. Physical examination remains the cornerstone of detection of recurrent breast cancer after reconstruction, and other modalities such as MRI should be used only as adjuncts to clarify any physical findings. In a meta-analysis including women who underwent mastectomy and reconstruction for breast cancer, MRI surveillance resulted in a cancer detection rate of 4.7 per 1000 screening exams, but only 1.1 per 1000 were clinically occult (nonpalpable) [<a href="#rid35">35</a>].</p><p>Although the FDA recommends MRI or ultrasound screening of silicone implant reconstructed breasts after five to six years and every two to three years thereafter for possible rupture, it is not clear how this impacts outcomes and recent data suggest that this is not routine practice [<a href="#rid38">38</a>]. MRI screening for rupture of implants is typically done without gadolinium, and would not detect most recurrences. (See  <a class="medical medical_review" href="/d/html/801.html" rel="external">"Overview of breast reconstruction", section on 'Surveillance of the reconstructed breast'</a>.)</p><p class="headingAnchor" id="H2692716"><span class="h3">Discontinuing breast imaging</span><span class="headingEndMark"> — </span>Continued screening mammography is warranted for older survivors with reasonable functional status and life expectancy [<a href="#rid39">39</a>]. The available data suggest that surveillance mammography reduces the risk of death from breast cancer, even among older women [<a href="#rid19">19,21</a>]. We adopt the following approach: imaging 6 to 12 months after completion of local therapy followed by mammography annually for healthy women versus cessation of screening mammography in patients whose life expectancy is less than 5 to 10 years [<a href="#rid40">40</a>].</p><p>One prospective study evaluated over 1800 women 65 years and older with stage I and II breast cancer and reported that each additional mammogram was associated with a significant reduction in the risk of dying from breast cancer (OR 0.69, 95% CI 0.52-0.92) [<a href="#rid19">19</a>]. A similar conclusion was reached in a study from the Surveillance, Epidemiology, and End Results (SEER)-Medicare database [<a href="#rid21">21</a>].</p><p class="headingAnchor" id="H435572081"><span class="h2">Evaluation of bone density</span><span class="headingEndMark"> — </span>Women with a history of breast cancer may be at increased risk of osteoporosis as a result of prior cancer treatment. Therefore, ASCO guidelines include performing a baseline screening evaluation (typically with dual energy X-ray absorptiometry) in the following patients [<a href="#rid41">41</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Women over age 65.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Women ages 60 to 64 in the presence of any of the following: a family history of osteoporosis, body weight &lt;70 kg, a history of a nontraumatic fracture, or other risk factors for osteoporosis (eg, smoking, a sedentary lifestyle, alcohol use).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Postmenopausal women taking an aromatase inhibitor (AI), including those in whom an AI has been recommended but not yet initiated.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Premenopausal women who develop treatment-related premature menopause.</p><p></p><p>However, it is not clear that bone density assessments are valuable at baseline if the patient already plans to initiate bisphosphonate or receptor activator of nuclear factor kappa-B ligand (RANKL) inhibitor therapy, regardless of the results. In that case, a bone density assessment at the completion of the bisphosphonate or RANKL inhibitor treatment may be of greater value, and this is our approach. Also, it is not clear what role vitamin D supplementation should play in women treated for breast cancer, nor whether levels should be checked routinely. In the absence of prospective data to inform the benefits specifically in these patients, the assessment of vitamin D levels and the role of vitamin D supplementation for women with low vitamin D levels should follow similar guidance as for women without a prior history of breast cancer. (See  <a class="medical medical_review" href="/d/html/2022.html" rel="external">"Vitamin D deficiency in adults: Definition, clinical manifestations, and treatment"</a> and  <a class="medical medical_review" href="/d/html/2023.html" rel="external">"Calcium and vitamin D supplementation in osteoporosis"</a>.)</p><p>Further discussion related to bone health, including the screening, treatment, and surveillance of osteoporosis, for women treated for breast cancer is discussed separately. (See  <a class="medical medical_review" href="/d/html/2046.html" rel="external">"Screening for osteoporosis in postmenopausal women and men"</a> and  <a class="medical medical_review" href="/d/html/776.html" rel="external">"Use of osteoclast inhibitors in early breast cancer"</a> and  <a class="medical medical_review" href="/d/html/2062.html" rel="external">"Evaluation and management of aromatase inhibitor-induced bone loss"</a>.)</p><p class="headingAnchor" id="H346411104"><span class="h2">Genetic counseling</span><span class="headingEndMark"> — </span>Breast cancer survivors who have not already pursued genetic testing may be appropriate candidates for testing. <em>BRCA</em> testing is an especially important consideration for men, and for women diagnosed at or under the age of 50, or with Ashkenazi heritage, and/or a strong family history of breast or ovarian cancer [<a href="#rid39">39</a>]. If the breast cancer was triple negative (not expressing estrogen receptor [ER], progesterone receptor [PR], or overexpressing human epidermal growth factor receptor 2 [HER2]), testing should be considered if a woman was diagnosed up to age 60. Prior to testing, it is important that patients be counseled about the potential ramifications of test results for themselves and their caregivers, both medically and psychosocially. (See  <a class="medical medical_review" href="/d/html/753.html" rel="external">"Genetic testing and management of individuals at risk of hereditary breast and ovarian cancer syndromes"</a> and  <a class="medical medical_review" href="/d/html/779.html" rel="external">"Breast cancer in men"</a>.)</p><p>Other rarer genetic syndromes that predispose to breast cancer and for which testing can be performed, depending on family and personal history of a variety of cancers, include Li-Fraumeni and Cowden syndromes. A genetic counselor can help to discern whether such testing might be in order. (See  <a class="medical medical_review" href="/d/html/14255.html" rel="external">"Li-Fraumeni syndrome"</a> and  <a class="medical medical_review" href="/d/html/16543.html" rel="external">"PTEN hamartoma tumor syndromes, including Cowden syndrome"</a>.)</p><p>Genetic testing of the breast cancer survivor is important, particularly to facilitate testing in other family members. Once a particular mutation has been identified, testing other family members is technically straightforward. While it is possible to begin the genetic testing process in an unaffected individual, there is a greater chance that these results will be inconclusive. Therefore, the breast cancer survivor should be tested, particularly if her own children and first-degree relatives are also interested in their personal genetic susceptibility. (See  <a class="medical medical_review" href="/d/html/2901.html" rel="external">"Genetic testing", section on 'Practical issues'</a>.)</p><p class="headingAnchor" id="H541712004"><span class="h2">Role of laboratory evaluation and other imaging</span><span class="headingEndMark"> — </span>Intensive laboratory and/or radiologic surveillance is not indicated for asymptomatic breast cancer survivors. This was demonstrated in a 2005 meta-analysis of two randomized trials that compared routine follow-up (regular physical examination and mammography) with intensive surveillance (including radiologic and laboratory testing) [<a href="#rid42">42</a>]. There was no difference between groups in overall survival (hazard ratio [HR] 0.96, 95% CI 0.80-1.15) or disease-free survival (HR 0.84, 95% CI 0.71-1.00).</p><p>Early diagnosis of metastatic disease, based on imaging alone and prior to onset of clinical signs or symptoms, may result in earlier intervention, with associated toxicities, but does not improve survival. Although a small percentage of patients with limited metastatic disease (eg, isolated pulmonary or liver metastases) may be treated with a multimodality approach, whether such patients are best identified by intensive post-treatment surveillance is unknown. Furthermore, laboratory and imaging tests used for surveillance have significant false-positive and false-negative rates and increased costs [<a href="#rid43">43</a>]. The unnecessary additional testing generated by a false-positive result and the misleading reassurance generated by a false-negative test can adversely affect the breast cancer survivor.</p><p>Therefore, we recommend <strong>against</strong> performing the following tests in asymptomatic women  (<a class="graphic graphic_table graphicRef61501" href="/d/graphic/61501.html" rel="external">table 1</a>) [<a href="#rid12">12</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Liver function tests</strong> – Routine liver function tests are falsely elevated in up to 80 percent of women without liver metastases [<a href="#rid44">44-46</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Serum tumor markers</strong> – A number of serum markers are available that can detect early breast cancer recurrence, including CA 15-3, carcinoembryonic antigen (CEA), and CA 27.29 [<a href="#rid47">47-50</a>]. These biochemical markers of breast cancer increase in conjunction with advancing primary disease stage and reflect the total body burden of disease  (<a class="graphic graphic_table graphicRef59985" href="/d/graphic/59985.html" rel="external">table 3</a>) [<a href="#rid51">51-54</a>]. However, they are neither sensitive nor specific for breast cancer relapse [<a href="#rid50">50,51</a>]. Therefore, measurement of serum tumor markers should only be used to monitor treatment response of patients with metastatic breast cancer in the absence of readily measurable advanced disease [<a href="#rid55">55</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Chest imaging</strong> – Neither chest radiograph nor computed tomography (CT) is recommended to screen for lung metastases in the asymptomatic patient [<a href="#rid56">56-58</a>]. In one series of 416 patients who were undergoing surveillance with routine chest imaging after completing primary treatment for breast cancer, only nine patients had isolated pulmonary metastases. [<a href="#rid59">59</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bone scan and serum alkaline phosphatase</strong> – There is no evidence that early detection of bone metastases changes the clinical course of the disease. Metastases to bone are almost always diagnosed by symptoms, even when patients undergo routine surveillance with bone scans [<a href="#rid60">60-63</a>]. Bone scans have an estimated sensitivity and specificity for detecting bone metastases of approximately 86 and 81 percent, respectively [<a href="#rid64">64</a>].</p><p></p><p class="bulletIndent1">Alkaline phosphatase is neither sensitive nor specific for bone metastases. In a series of 1601 patients with node-positive breast cancer, alkaline phosphatase was only elevated in one-half of those patients who had known skeletal metastases, while the test was abnormal in 28 percent of those without bone metastases [<a href="#rid63">63</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Abdominopelvic imaging</strong> – Neither liver ultrasound nor abdominopelvic CT scans is recommended as a routine component of post-treatment surveillance [<a href="#rid65">65-67</a>]. In one large series of over 2400 patients that included 6628 pelvic CT scans performed over a nine-year period, pelvic metastases were the only site of metastatic disease in 13 (0.5 percent) [<a href="#rid66">66</a>]. However, the findings led to over 200 additional radiographic and 50 surgical procedures, of which 84 percent yielded benign or negative results.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>PET scanning</strong> – There is no role for positron emission tomography (PET) scan in post-treatment follow-up. In retrospective cohort studies and a meta-analysis of 16 studies, PET scanning has been consistently more sensitive than conventional imaging and serum tumor markers for early diagnosis of recurrent disease [<a href="#rid68">68-70</a>]. However, the impact on survival and quality of life has not been addressed, and it seems unlikely that this approach would provide a survival or quality-of-life benefit.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA)</strong> – Available evidence does not support the use of tumor markers, CTCs, or, more recently available, ctDNA to evaluate for recurrence after treatment for primary breast cancer [<a href="#rid55">55</a>]. Although the presence of CTCs has been associated with worsened prognosis for those with early breast cancer, data are limited and do not support their use for routine clinical decision-making regarding adjuvant treatments or evaluation for recurrence. The presence of ctDNA has also been associated with recurrence in early and later follow-up after treatment for early breast cancer; however, the limited available data do not support routine use for decision-making in follow-up [<a href="#rid71">71-73</a>]. (See  <a class="medical medical_review" href="/d/html/782.html" rel="external">"Prognostic and predictive factors in early, non-metastatic breast cancer", section on 'Disseminated and circulating tumor cells'</a>.)</p><p></p><p class="headingAnchor" id="H541711995"><span class="h1">PROMOTING A HEALTHY LIFESTYLE</span><span class="headingEndMark"> — </span>Patients often ask what they can do to improve their overall outcome from breast cancer. Lifestyle modification can be an empowering and effective way to boost physical and mental health in breast cancer survivors and possibly to improve disease and overall mortality outcomes. Observational data suggest that exercise, avoidance of obesity, and minimization of alcohol intake are associated with a decreased risk of breast cancer recurrence and death in survivors [<a href="#rid74">74-77</a>].</p><p class="headingAnchor" id="H128691"><span class="h2">Physical activity, diet, and body weight</span><span class="headingEndMark"> — </span>Diet, physical activity, and weight are collectively considered energy balance factors because they describe the relationship between energy consumed (diet), energy expended (physical activity), and energy stored (adiposity). They have each been linked to cancer outcomes, particularly in survivors of breast cancer. (See  <a class="medical medical_review" href="/d/html/14222.html" rel="external">"The roles of diet, physical activity, and body weight in cancer survivors"</a>.)</p><p>One nutritional issue of interest to breast cancer survivors is the impact of soy products (which contain phytoestrogens) on breast cancer recurrence rates. Although there is no convincing evidence that soy affects the risk of recurrence, the theoretical risk that phytoestrogens could stimulate the growth of hormonally sensitive cancers raises the concern that high soy intake could be dangerous. Thus, moderation of soy intake is generally suggested. (See  <a class="medical medical_review" href="/d/html/792.html" rel="external">"Factors that modify breast cancer risk in women"</a>.)</p><p>The safety and efficacy of many other nutritional complementary therapies including mistletoe, high doses of vitamins, and trace elements like <a class="drug drug_general" data-topicid="9884" href="/d/drug information/9884.html" rel="external">selenium</a>, zinc, and copper remains uncertain [<a href="#rid78">78</a>] (see  <a class="medical medical_review" href="/d/html/2831.html" rel="external">"Overview of complementary, alternative, and integrative medicine practices in oncology care, and potential risks and harm"</a>). Higher vitamin D levels at the time of diagnosis have been associated with better prognosis, especially in premenopausal women [<a href="#rid79">79</a>], but there are no randomized controlled trial data available to inform the potential impact of vitamin D supplementation on risk of recurrence.</p><p class="headingAnchor" id="H128834"><span class="h2">Complementary therapies</span><span class="headingEndMark"> — </span>Complementary therapies, including acupressure and mindfulness, music therapy, and yoga have been explored as treatments in cancer survivors. While there is no evidence that these interventions decrease recurrences, they may improve quality of life and mood [<a href="#rid80">80</a>].</p><p>In one trial of 424 survivors of nonmetastatic breast cancer randomly assigned to self-administered relaxing acupressure, stimulating acupressure, or usual care, both acupressure arms reduced persistent fatigue, and relaxing acupressure also improved sleep quality and quality of life [<a href="#rid81">81</a>]. Randomized trial data suggest some improvement of joint pain with true versus sham acupuncture among women on aromatase inhibitors [<a href="#rid82">82</a>]. (See  <a class="medical medical_review" href="/d/html/749.html" rel="external">"Adjuvant endocrine and targeted therapy for postmenopausal women with hormone receptor-positive breast cancer", section on 'Side effects'</a>.)</p><p>Although breast cancer survivors may experience psychologic and physical side effects from their cancer diagnosis and treatment, some evidence suggests improvement in these symptoms with the practice of mindfulness [<a href="#rid83">83-87</a>]. Mindfulness involves being aware and accepting of one's present experiences, including thoughts, feelings, and physical sensations [<a href="#rid84">84</a>]. In one study of 322 breast cancer survivors randomly assigned to a six-week mindfulness-based stress reduction program or usual care, patients in the study group experienced improvement in a broad range of symptoms, including fear of recurrence, anxiety, and fatigue [<a href="#rid83">83</a>]. In another trial of 71 patients, mindfulness practices over six weeks led to reductions in stress and markers of inflammation. Improvements in fatigue, sleep, vasomotor symptoms, and affect were also observed [<a href="#rid84">84</a>]. However, at three-month follow-up, many of these benefits were not maintained, suggesting that ongoing practice of these techniques rather than one-time participation in a training program may be key to promoting lasting benefits. Long-term data on mindfulness practices as well as their applicability to a broader population of breast cancer survivors are pending.</p><p class="headingAnchor" id="H128815"><span class="h2">Alcohol intake</span><span class="headingEndMark"> — </span>The evidence that alcohol is associated with an increase in the risk of recurrence is limited [<a href="#rid77">77,88-90</a>]. In the largest study, 1897 female breast cancer survivors (on average two years postdiagnosis) participated in the Life After Cancer Epidemiology (LACE) study [<a href="#rid77">77</a>]. Those who drank ≥6 g of alcohol daily (equivalent to at least three to four alcoholic drinks per week) had significantly higher rates of recurrence (hazard ratio [HR] 1.35, 95% CI 1.0-1.83) and death due to breast cancer (HR 1.51, 95% CI 1.0-2.29) than those who drank &lt;0.5 g daily. Overweight and postmenopausal women seemed to experience the greatest harm from alcohol intake as measured by breast cancer recurrence risk. (See  <a class="medical medical_review" href="/d/html/2781.html" rel="external">"Overview of the risks and benefits of alcohol consumption", section on 'Breast cancer'</a>.)</p><p class="headingAnchor" id="H346411119"><span class="h1">REPRODUCTIVE ISSUES</span></p><p class="headingAnchor" id="H346411135"><span class="h2">Fertility and pregnancy after breast cancer</span><span class="headingEndMark"> — </span>Young breast cancer survivors may experience infertility after breast cancer due to chemotherapy-related gonadotoxicity and the delay in childbearing required when women are taking hormonal therapy. Fertility outcomes among breast cancer survivors are discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/4801.html" rel="external">"Overview of infertility and pregnancy outcome in cancer survivors"</a> and  <a class="medical medical_review" href="/d/html/7440.html" rel="external">"Fertility and reproductive hormone preservation: Overview of care prior to gonadotoxic therapy or surgery"</a>.)</p><p>Cancer outcomes and recommendations regarding timing of attempted pregnancy are discussed here:</p><p class="bulletIndent1"><span class="glyph">●</span>We typically advise women to wait for at least two years from the time of the diagnosis before attempting pregnancy [<a href="#rid91">91-93</a>]. The primary reason for this approach is to see that the patient does not have early cancer recurrence. Some data suggest that pregnancy sooner than two years is safe [<a href="#rid94">94-96</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients with hormone receptor-positive breast cancer are treated with adjuvant hormone therapy. A recent study found that temporary interruption of adjuvant endocrine therapy does not confer a greater risk of breast cancer risk in the short term [<a href="#rid97">97</a>], but longer term data are required.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The study examined cancer recurrence rates among 516 patients desiring pregnancy who had received adjuvant endocrine therapy for 18 to 30 months for stage I to III breast cancer [<a href="#rid97">97</a>]. The duration of interruption of endocrine therapy could be up to two years to allow for attempting pregnancy, delivery, and breastfeeding. The median time from cancer diagnosis to study enrollment was 29 months. Most patients (94 percent) had stage I or II disease. At a median follow-up of 41 months:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Seventy-four percent had at least one pregnancy and 64 percent had at least one live birth.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>The three-year incidence of breast cancer events was 8.9 percent in patients in this study versus 9.2 percent in an external control cohort of patients who would have met entry criteria but did not interrupt endocrine treatment for pregnancy.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Half of patients had resumed therapy within 26 months after treatment interruption.</p><p></p><p class="bulletIndent1">Reassuringly, prior breast cancer treatments do not appear to increase the risk of congenital malformation [<a href="#rid98">98</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>However, due to risks for teratogenicity, we encourage women with a history of hormone receptor-positive breast cancer to wait at least three months from cessation of <a class="drug drug_general" data-topicid="9972" href="/d/drug information/9972.html" rel="external">tamoxifen</a> (with or without ovarian suppression medication or an aromatase inhibitor and ovarian suppression medication, by extrapolation) before attempting pregnancy. (See  <a class="medical medical_review" href="/d/html/15801.html" rel="external">"Gestational breast cancer: Treatment", section on 'Endocrine therapy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Women who were treated with <a class="drug drug_general" data-topicid="10101" href="/d/drug information/10101.html" rel="external">trastuzumab</a> for a human epidermal growth factor receptor 2 (HER2)-positive breast cancer should utilize effective contraception for at least seven months after the end of trastuzumab before attempting pregnancy because of trastuzumab-related oligohydramnios to the fetus, which could result in pulmonary hypoplasia and neonatal death. These data and other prescribing information are discussed separately. (See  <a class="medical medical_review" href="/d/html/773.html" rel="external">"Adjuvant systemic therapy for HER2-positive breast cancer", section on 'Prescribing information and formulations'</a>.)</p><p></p><p>For women with a history of breast cancer, a subsequent pregnancy does not appear to compromise survival [<a href="#rid94">94,99-102</a>]. In a systematic review of 36 studies including over 112,000 patients with breast cancer, of whom 7505 had subsequent pregnancy, those with a pregnancy had better disease-free survival (HR 0.66) and overall survival (0.56) than those without pregnancy, trends that persisted even after correcting for potential confounders, including patient, tumor, treatment characteristics, and timing of pregnancy [<a href="#rid103">103</a>]. Similar results were observed in a 2011 retrospective analysis of 14 case-control studies [<a href="#rid99">99</a>]. The improved cancer outcomes are likely explained by a selection bias known as the "healthy mother effect," such that only healthy breast cancer survivors were able to conceive and carry a pregnancy [<a href="#rid96">96</a>].</p><p>In addition, a case-control study suggests that pregnancy after breast cancer is safe regardless of estrogen receptor status [<a href="#rid102">102</a>].</p><p>Similar data now exist for women who are breast cancer susceptibility gene (<em>BRCA</em>) carriers with a history of breast cancer, and we offer similar counseling. Retrospective cohort studies of such women showed that pregnancy was not associated with increased risks of breast cancer recurrence or pregnancy complications [<a href="#rid104">104,105</a>].</p><p class="headingAnchor" id="H269850350"><span class="h2">Contraception after breast cancer</span><span class="headingEndMark"> — </span>The World Health Organization guidelines for medical eligibility for contraceptive use have recommended avoiding hormonal contraception in women with a current or past history of breast cancer (particularly in those with hormone receptor-positive disease)  (<a class="graphic graphic_table graphicRef60832" href="/d/graphic/60832.html" rel="external">table 4</a>). Although this is our typical practice, we do make exceptions to this approach. Specifically, although we first suggest use of a nonhormonal contraceptive method (condom, diaphragm, <a class="drug drug_general" data-topicid="93719" href="/d/drug information/93719.html" rel="external">copper intrauterine device</a> [IUD]), some patients may reasonably opt for a low-dose levonorgestrel-releasing contraception device (LNG-IUD), either for contraception or endometrial protection on <a class="drug drug_general" data-topicid="9972" href="/d/drug information/9972.html" rel="external">tamoxifen</a>. Patients with a low risk of recurrence, double mastectomy, or remote history of cancer may be appropriate candidates for this option, depending on their values and preferences. If a patient is interested in an LNG-IUD, we discuss that the systemic absorption of hormone is likely to be low, although the safety and efficacy of such an approach has not been well validated. (See  <a class="medical medical_review" href="/d/html/5459.html" rel="external">"Contraception: Counseling and selection", section on 'Special populations'</a>.)</p><p>The reason for the limitations in available data is that women with breast cancer have traditionally been excluded from studies of hormonal contraceptives. The LNG-IUD has been evaluated in women with a history of breast cancer, although primarily as a method of endometrial protection from the effects of <a class="drug drug_general" data-topicid="9972" href="/d/drug information/9972.html" rel="external">tamoxifen</a> rather than as a contraceptive modality. Data are limited and inconclusive. For example, one retrospective cohort study of breast cancer survivors suggested an increased risk of recurrence among cases (LNG-IUD users, n = 79) over controls (those who did not use LNG-IUD, n = 120) [<a href="#rid106">106</a>]. The rate of breast cancer recurrence was higher in cases compared with matched controls (22 versus 17 percent; odds ratio [OR] 1.86, 95% CI 0.86-4.00), although the difference was not statistically significant. However, other data suggest that progesterone-eluting IUDs may be safe and prevent endometrial pathology in premenopausal women on tamoxifen [<a href="#rid107">107</a>]. (See  <a class="medical medical_review" href="/d/html/764.html" rel="external">"Managing the side effects of tamoxifen and aromatase inhibitors", section on 'Tamoxifen'</a>.)</p><p class="headingAnchor" id="H319241104"><span class="h1">CARDIOMETABOLIC ISSUES</span><span class="headingEndMark"> — </span>Patients who have been treated for breast cancer are at risk for cardiometabolic effects [<a href="#rid108">108,109</a>], including hypertension, diabetes, and dyslipidemia. Routine screening and follow-up for these issues in the primary care setting is appropriate. (See  <a class="medical medical_review" href="/d/html/90854.html" rel="external">"Clinical manifestations, diagnosis, and treatment of anthracycline-induced cardiotoxicity"</a> and  <a class="medical medical_review" href="/d/html/774.html" rel="external">"Cardiotoxicity of trastuzumab and other HER2-targeted agents"</a> and  <a class="medical medical_review" href="/d/html/7062.html" rel="external">"Cardiotoxicity of radiation therapy for breast cancer and other malignancies"</a>.)</p><p>In one study including almost 15,000 patients with newly diagnosed breast cancer and 75,000 matched controls, breast cancer patients had a higher incidence of hypertension (10.9 versus 8.9 percent) and diabetes (2.1 versus 1.7 percent) after two years, with higher diabetes incidence persisting after ten years (9.3 versus 8.8 percent); risk of hyperlipidemia was not increased [<a href="#rid108">108</a>]. Although this study was conducted in an integrated health care delivery system and adjusted for primary care utilization prior to diagnosis, surveillance bias must be considered (breast cancer survivors are seen more frequently in the health care system, as part of routine surveillance).</p><p class="headingAnchor" id="H604338985"><span class="h1">QUALITY OF LIFE</span><span class="headingEndMark"> — </span>Quality of life is a multidimensional construct that takes into account the physical, mental, social, economic, and spiritual aspects of life. Limited data suggest that patients treated for breast cancer have good quality of life, particularly as they move beyond the treatment period [<a href="#rid4">4,13,110,111</a>]. However, they may continue to have some lingering concerns. For example, in one study that included over 280 long-term survivors (without evidence of a recurrence &gt;7 years) compared with almost 170 controls (without a history of breast cancer), self-reported deficits appeared to be limited to issues related to cognitive functioning and finances [<a href="#rid110">110</a>]. Young women (age &lt;40 years at diagnosis) may be particularly at risk for decline in quality of life after breast cancer, and attention to their life stage-related concerns (including fertility as well as psychosocial issues) is warranted in follow-up [<a href="#rid112">112</a>].</p><p>Multiple studies have shown that exercise improves quality of life in breast cancer survivors. Therefore, patients should be encouraged to adopt a physically active lifestyle following treatment for breast cancer. Further discussion on the role of physical activity in breast cancer survivors is discussed separately. (See  <a class="medical medical_review" href="/d/html/14222.html" rel="external">"The roles of diet, physical activity, and body weight in cancer survivors"</a>.)</p><p class="headingAnchor" id="H12070561"><span class="h1">COORDINATION OF CARE</span><span class="headingEndMark"> — </span>If agreed upon by the patient, the treating oncologist, and the primary care physician (PCP), shared care would provide treatment summary information and a plan for follow-up care to both the patient and the PCP. The level of shared follow-up by the oncology specialist and PCP could depend upon patient and provider preferences. Communication between the PCP and subspecialist is vital given that uncertainties about clinician roles and responsibilities can lead to deficiencies in care [<a href="#rid4">4</a>]. (See  <a class="medical medical_review" href="/d/html/16613.html" rel="external">"Overview of cancer survivorship care for primary care and oncology providers", section on 'Coordination of care'</a> and  <a class="medical medical_review" href="/d/html/17020.html" rel="external">"Assuring quality of care for cancer survivors: The survivorship care plan"</a>.)</p><p class="headingAnchor" id="H3748590079"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/113775.html" rel="external">"Society guideline links: Breast cancer"</a>.)</p><p class="headingAnchor" id="H17719415"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/d/html/882.html" rel="external">"Patient education: Lymphedema after cancer surgery (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H566671"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Introduction</strong> – Essential elements of management for breast cancer survivors who have completed active treatment and have no evidence of disease are cancer surveillance, encouragement of adherence with ongoing treatment and lifestyle recommendations, treatment of medical and psychosocial consequences of cancer and its therapy, and care coordination between specialists and primary care providers (PCPs). (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Components of follow-up and counseling</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Survivor follow-up should include updated history, regular physical examination, and breast imaging (ie, mammography). The follow-up should not only focus on cancer surveillance, but also on any late-treatment-related complications, psychosocial issues, and occupational problems. (See <a class="local">'Components of follow-up'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>All women with breast cancer should be counseled about the role of genetic testing and counseling. (See <a class="local">'Genetic counseling'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Laboratory studies or radiologic imaging to screen for distant recurrence in asymptomatic patients should not be performed. (See <a class="local">'Role of laboratory evaluation and other imaging'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>All breast cancer survivors should pursue a healthy lifestyle that includes following a prudent diet, pursuing or maintaining an active exercise program, minimizing alcohol intake, and refraining from smoking. (See <a class="local">'Promoting a healthy lifestyle'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Reproductive issues</strong> – Although data are limited, studies do not indicate an increased risk of recurrence for survivors who become pregnant or have an impact on pregnancy outcomes. (See <a class="local">'Reproductive issues'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>We typically advise women to wait for at least two years from diagnosis before attempting pregnancy.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For women with breast cancer who wish to prevent pregnancy, we suggest not administering hormonal contraception (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Although this is our typical practice, we do make exceptions to this approach. Specifically, although we first suggest use of a nonhormonal contraceptive method (condom, diaphragm, <a class="drug drug_general" data-topicid="93719" href="/d/drug information/93719.html" rel="external">copper intrauterine device</a> [IUD]), some patients may reasonably opt for a low-dose levonorgestrel-releasing contraception device (LNG-IUD), either for contraception or endometrial protection on <a class="drug drug_general" data-topicid="9972" href="/d/drug information/9972.html" rel="external">tamoxifen</a>. Clinicians should counsel women about methods most consistent with their lifestyles and beliefs. (See <a class="local">'Contraception after breast cancer'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Coordination of care</strong> – A variety of clinicians may adequately follow women after their primary therapy for breast cancer. Clinicians should be experienced in the surveillance of these patients, the complications that may arise from treatment, and breast examination, including the examination of irradiated breasts. A shared care model that integrates both specialists and PCPs in ongoing follow-up care may provide the best adherence to guidelines for recommended care, but communication and coordination of care is required. (See <a class="local">'Coordination of care'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">World Health Organization International Agency for Research on Cancer. The Global Cancer Observatory. 2018 statistics. Available at: http://gco.iarc.fr/today/data/factsheets/populations/900-world-fact-sheets.pdf (Accessed on January 17, 2019).</li><li><a class="nounderline abstract_t">Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin 2023; 73:17.</a></li><li><a class="nounderline abstract_t">Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin 2018; 68:7.</a></li><li><a class="nounderline abstract_t">Cheung WY, Neville BA, Cameron DB, et al. Comparisons of patient and physician expectations for cancer survivorship care. J Clin Oncol 2009; 27:2489.</a></li><li class="breakAll">National Coalition for Cancer Survivorship. Available at: https://www.canceradvocacy.org/about/ (Accessed on March 15, 2016).</li><li class="breakAll">Survivor. Dictionary of Cancer Terms. National Cancer Institute. Available at: http://www.cancer.gov/dictionary?cdrid=450125 (Accessed on July 17, 2012).</li><li><a class="nounderline abstract_t">Miller KD, Nogueira L, Devasia T, et al. Cancer treatment and survivorship statistics, 2022. CA Cancer J Clin 2022; 72:409.</a></li><li><a class="nounderline abstract_t">Khatcheressian JL, Hurley P, Bantug E, et al. Breast cancer follow-up and management after primary treatment: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 2013; 31:961.</a></li><li><a class="nounderline abstract_t">de Bock GH, Bonnema J, van der Hage J, et al. Effectiveness of routine visits and routine tests in detecting isolated locoregional recurrences after treatment for early-stage invasive breast cancer: a meta-analysis and systematic review. J Clin Oncol 2004; 22:4010.</a></li><li><a class="nounderline abstract_t">Montgomery DA, Krupa K, Cooke TG. Follow-up in breast cancer: does routine clinical examination improve outcome? A systematic review of the literature. Br J Cancer 2007; 97:1632.</a></li><li><a class="nounderline abstract_t">Lu W, de Bock GH, Schaapveld M, et al. The value of routine physical examination in the follow up of women with a history of early breast cancer. Eur J Cancer 2011; 47:676.</a></li><li><a class="nounderline abstract_t">Runowicz CD, Leach CR, Henry NL, et al. American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline. J Clin Oncol 2016; 34:611.</a></li><li><a class="nounderline abstract_t">Montgomery DA, Krupa K, Cooke TG. Alternative methods of follow up in breast cancer: a systematic review of the literature. Br J Cancer 2007; 96:1625.</a></li><li><a class="nounderline abstract_t">Loomer L, Brockschmidt JK, Muss HB, Saylor G. Postoperative follow-up of patients with early breast cancer. Patterns of care among clinical oncologists and a review of the literature. Cancer 1991; 67:55.</a></li><li><a class="nounderline abstract_t">Pace BW, Tinker MA. Follow-up of patients with breast cancer. Clin Obstet Gynecol 1994; 37:998.</a></li><li><a class="nounderline abstract_t">Temple LK, Wang EE, McLeod RS. Preventive health care, 1999 update: 3. Follow-up after breast cancer. Canadian Task Force on Preventive Health Care. CMAJ 1999; 161:1001.</a></li><li><a class="nounderline abstract_t">Yang SH, Yang KH, Li YP, et al. Breast conservation therapy for stage I or stage II breast cancer: a meta-analysis of randomized controlled trials. Ann Oncol 2008; 19:1039.</a></li><li><a class="nounderline abstract_t">Grunfeld E, Noorani H, McGahan L, et al. Surveillance mammography after treatment of primary breast cancer: a systematic review. Breast 2002; 11:228.</a></li><li><a class="nounderline abstract_t">Lash TL, Fox MP, Buist DS, et al. Mammography surveillance and mortality in older breast cancer survivors. J Clin Oncol 2007; 25:3001.</a></li><li class="breakAll">American College of Radiology. ACR Appropriateness Criteria. Stage I breast cancer: Initial workup and surveillance for local recurrence and distant metastases in asymptomatic women. Available at: https://acsearch.acr.org/docs/69496/Narrative/ (Accessed on February 10, 2020).</li><li><a class="nounderline abstract_t">Schootman M, Jeffe DB, Lian M, et al. Surveillance mammography and the risk of death among elderly breast cancer patients. Breast Cancer Res Treat 2008; 111:489.</a></li><li><a class="nounderline abstract_t">Lash TL, Fox MP, Silliman RA. Reduced mortality rate associated with annual mammograms after breast cancer therapy. Breast J 2006; 12:2.</a></li><li><a class="nounderline abstract_t">Orel SG, Fowble BL, Solin LJ, et al. Breast cancer recurrence after lumpectomy and radiation therapy for early-stage disease: prognostic significance of detection method. Radiology 1993; 188:189.</a></li><li><a class="nounderline abstract_t">Abner AL, Recht A, Eberlein T, et al. Prognosis following salvage mastectomy for recurrence in the breast after conservative surgery and radiation therapy for early-stage breast cancer. J Clin Oncol 1993; 11:44.</a></li><li><a class="nounderline abstract_t">Montgomery DA, Krupa K, Jack WJ, et al. Changing pattern of the detection of locoregional relapse in breast cancer: the Edinburgh experience. Br J Cancer 2007; 96:1802.</a></li><li><a class="nounderline abstract_t">Houssami N, Abraham LA, Miglioretti DL, et al. Accuracy and outcomes of screening mammography in women with a personal history of early-stage breast cancer. JAMA 2011; 305:790.</a></li><li><a class="nounderline abstract_t">Mellink WA, Holland R, Hendriks JH, et al. The contribution of routine follow-up mammography to an early detection of asynchronous contralateral breast cancer. Cancer 1991; 67:1844.</a></li><li><a class="nounderline abstract_t">Gutter Z. Cancer of the remaining breast: radiologic contribution to diagnosis. Can Med Assoc J 1976; 114:27.</a></li><li><a class="nounderline abstract_t">Senofsky GM, Wanebo HJ, Wilhelm MC, et al. Has monitoring of the contralateral breast improved the prognosis in patients treated for primary breast cancer? Cancer 1986; 57:597.</a></li><li><a class="nounderline abstract_t">Saslow D, Boetes C, Burke W, et al. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin 2007; 57:75.</a></li><li><a class="nounderline abstract_t">Runowicz CD, Leach CR, Henry NL, et al. American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline. CA Cancer J Clin 2016; 66:43.</a></li><li><a class="nounderline abstract_t">Monticciolo DL, Newell MS, Moy L, et al. Breast Cancer Screening for Women at Higher-Than-Average Risk: Updated Recommendations From the ACR. J Am Coll Radiol 2023; 20:902.</a></li><li class="breakAll">BC Cancer Agency: Clinical indications for breast MRI. Available at: http://www.bccancer.bc.ca/HPI/CancerManagementGuidelines/Breast/Diagnosis/MRI.htm (Accessed on August 28, 2012).</li><li><a class="nounderline abstract_t">Quinn EM, Coveney AP, Redmond HP. Use of magnetic resonance imaging in detection of breast cancer recurrence: a systematic review. Ann Surg Oncol 2012; 19:3035.</a></li><li><a class="nounderline abstract_t">Smith D, Sepehr S, Karakatsanis A, et al. Yield of Surveillance Imaging After Mastectomy With or Without Reconstruction for Patients With Prior Breast Cancer: A Systematic Review and Meta-analysis. JAMA Netw Open 2022; 5:e2244212.</a></li><li><a class="nounderline abstract_t">Berg WA, Zhang Z, Lehrer D, et al. Detection of breast cancer with addition of annual screening ultrasound or a single screening MRI to mammography in women with elevated breast cancer risk. JAMA 2012; 307:1394.</a></li><li><a class="nounderline abstract_t">Barnsley GP, Grunfeld E, Coyle D, Paszat L. Surveillance mammography following the treatment of primary breast cancer with breast reconstruction: a systematic review. Plast Reconstr Surg 2007; 120:1125.</a></li><li class="breakAll">Few Patients Undergo Recommended MRI Screening After Silicone Implant Breast Surgery. Available at: https://www.plasticsurgery.org/news/press-releases/few-patients-undergo-recommended-mri-screening-after-silicone-implant-breast-surgery (Accessed on January 20, 2023).</li><li class="breakAll">National Comprehensive Cancer Network. Available at: www.nccn.org (Accessed on July 23, 2019).</li><li><a class="nounderline abstract_t">Freedman RA, Keating NL, Partridge AH, et al. Surveillance Mammography in Older Patients With Breast Cancer-Can We Ever Stop?: A Review. JAMA Oncol 2017; 3:402.</a></li><li><a class="nounderline abstract_t">Pant S, Shapiro CL. Aromatase inhibitor-associated bone loss: clinical considerations. Drugs 2008; 68:2591.</a></li><li><a class="nounderline abstract_t">Rojas MP, Telaro E, Russo A, et al. Follow-up strategies for women treated for early breast cancer. Cochrane Database Syst Rev 2005; :CD001768.</a></li><li><a class="nounderline abstract_t">Henry NL, Hayes DF, Ramsey SD, et al. Promoting quality and evidence-based care in early-stage breast cancer follow-up. J Natl Cancer Inst 2014; 106:dju034.</a></li><li><a class="nounderline abstract_t">Schreve RH, Terpstra OT, Ausema L, et al. Detection of liver metastases. A prospective study comparing liver enzymes, scintigraphy, ultrasonography and computed tomography. Br J Surg 1984; 71:947.</a></li><li><a class="nounderline abstract_t">Kemeny MM, Sugarbaker PH, Smith TJ, et al. A prospective analysis of laboratory tests and imaging studies to detect hepatic lesions. Ann Surg 1982; 195:163.</a></li><li><a class="nounderline abstract_t">Wiener SN, Sachs SH. An assessment of routine liver scanning in patients with breast cancer. Arch Surg 1978; 113:126.</a></li><li><a class="nounderline abstract_t">Chan DW, Beveridge RA, Muss H, et al. Use of Truquant BR radioimmunoassay for early detection of breast cancer recurrence in patients with stage II and stage III disease. J Clin Oncol 1997; 15:2322.</a></li><li><a class="nounderline abstract_t">Molina R, Zanón G, Filella X, et al. Use of serial carcinoembryonic antigen and CA 15.3 assays in detecting relapses in breast cancer patients. Breast Cancer Res Treat 1995; 36:41.</a></li><li><a class="nounderline abstract_t">Jäger W, Krämer S, Palapelas V, Norbert L. Breast cancer and clinical utility of CA 15-3 and CEA. Scand J Clin Lab Invest Suppl 1995; 221:87.</a></li><li><a class="nounderline abstract_t">Kokko R, Holli K, Hakama M. Ca 15-3 in the follow-up of localised breast cancer: a prospective study. Eur J Cancer 2002; 38:1189.</a></li><li><a class="nounderline abstract_t">Emens LA, Davidson NE. The follow-up of breast cancer. Semin Oncol 2003; 30:338.</a></li><li><a class="nounderline abstract_t">Nicolini A, Tartarelli G, Carpi A, et al. Intensive post-operative follow-up of breast cancer patients with tumour markers: CEA, TPA or CA15.3 vs MCA and MCA-CA15.3 vs CEA-TPA-CA15.3 panel in the early detection of distant metastases. BMC Cancer 2006; 6:269.</a></li><li><a class="nounderline abstract_t">Valenzuela P, Mateos S, Tello E, et al. The contribution of the CEA marker to CA 15.3 in the follow-up of breast cancer. Eur J Gynaecol Oncol 2003; 24:60.</a></li><li><a class="nounderline abstract_t">Guadagni F, Ferroni P, Carlini S, et al. A re-evaluation of carcinoembryonic antigen (CEA) as a serum marker for breast cancer: a prospective longitudinal study. Clin Cancer Res 2001; 7:2357.</a></li><li><a class="nounderline abstract_t">Harris L, Fritsche H, Mennel R, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 2007; 25:5287.</a></li><li><a class="nounderline abstract_t">Hurria A, Leung D, Trainor K, et al. Screening chest imaging studies are not effective in the follow-up of breast cancer patients. J Oncol Manag 2003; 12:13.</a></li><li><a class="nounderline abstract_t">Kokko R, Hakama M, Holli K. Role of chest X-ray in diagnosis of the first breast cancer relapse: a randomized trial. Breast Cancer Res Treat 2003; 81:33.</a></li><li><a class="nounderline abstract_t">Mehta VK, Goffinet DR. Unsuspected abnormalities noted on CT treatment-planning scans obtained for breast and chest wall irradiation. Int J Radiat Oncol Biol Phys 2001; 49:723.</a></li><li><a class="nounderline abstract_t">Rutgers EJ, van Slooten EA, Kluck HM. Follow-up after treatment of primary breast cancer. Br J Surg 1989; 76:187.</a></li><li><a class="nounderline abstract_t">Hannisdal E, Gundersen S, Kvaløy S, et al. Follow-up of breast cancer patients stage I-II: a baseline strategy. Eur J Cancer 1993; 29A:992.</a></li><li><a class="nounderline abstract_t">Tomin R, Donegan WL. Screening for recurrent breast cancer--its effectiveness and prognostic value. J Clin Oncol 1987; 5:62.</a></li><li><a class="nounderline abstract_t">Wickerham L, Fisher B, Cronin W. The efficacy of bone scanning in the follow-up of patients with operable breast cancer. Breast Cancer Res Treat 1984; 4:303.</a></li><li><a class="nounderline abstract_t">Pedrazzini A, Gelber R, Isley M, et al. First repeated bone scan in the observation of patients with operable breast cancer. J Clin Oncol 1986; 4:389.</a></li><li><a class="nounderline abstract_t">Yang HL, Liu T, Wang XM, et al. Diagnosis of bone metastases: a meta-analysis comparing ¹⁸FDG PET, CT, MRI and bone scintigraphy. Eur Radiol 2011; 21:2604.</a></li><li><a class="nounderline abstract_t">Impact of follow-up testing on survival and health-related quality of life in breast cancer patients. A multicenter randomized controlled trial. The GIVIO Investigators. JAMA 1994; 271:1587.</a></li><li><a class="nounderline abstract_t">Drotman MB, Machnicki SC, Schwartz LH, et al. Breast cancer: assessing the use of routine pelvic CT in patient evaluation. AJR Am J Roentgenol 2001; 176:1433.</a></li><li><a class="nounderline abstract_t">Kauczor HU, Voges EM, Wieland-Schneider C, et al. Value of routine abdominal and lymph node sonography in the follow-up of breast cancer patients. Eur J Radiol 1994; 18:104.</a></li><li><a class="nounderline abstract_t">Vranjesevic D, Filmont JE, Meta J, et al. Whole-body (18)F-FDG PET and conventional imaging for predicting outcome in previously treated breast cancer patients. J Nucl Med 2002; 43:325.</a></li><li><a class="nounderline abstract_t">Kamel EM, Wyss MT, Fehr MK, et al. [18F]-Fluorodeoxyglucose positron emission tomography in patients with suspected recurrence of breast cancer. J Cancer Res Clin Oncol 2003; 129:147.</a></li><li><a class="nounderline abstract_t">Isasi CR, Moadel RM, Blaufox MD. A meta-analysis of FDG-PET for the evaluation of breast cancer recurrence and metastases. Breast Cancer Res Treat 2005; 90:105.</a></li><li><a class="nounderline abstract_t">Parsons HA, Rhoades J, Reed SC, et al. Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer. Clin Cancer Res 2020; 26:2556.</a></li><li><a class="nounderline abstract_t">Lipsyc-Sharf M, de Bruin EC, Santos K, et al. Circulating Tumor DNA and Late Recurrence in High-Risk Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer. J Clin Oncol 2022; 40:2408.</a></li><li><a class="nounderline abstract_t">Garcia-Murillas I, Chopra N, Comino-Méndez I, et al. Assessment of Molecular Relapse Detection in Early-Stage Breast Cancer. JAMA Oncol 2019; 5:1473.</a></li><li><a class="nounderline abstract_t">Friedenreich CM, Gregory J, Kopciuk KA, et al. Prospective cohort study of lifetime physical activity and breast cancer survival. Int J Cancer 2009; 124:1954.</a></li><li><a class="nounderline abstract_t">Holick CN, Newcomb PA, Trentham-Dietz A, et al. Physical activity and survival after diagnosis of invasive breast cancer. Cancer Epidemiol Biomarkers Prev 2008; 17:379.</a></li><li><a class="nounderline abstract_t">Chlebowski RT, Aiello E, McTiernan A. Weight loss in breast cancer patient management. J Clin Oncol 2002; 20:1128.</a></li><li><a class="nounderline abstract_t">Kwan ML, Kushi LH, Weltzien E, et al. Alcohol consumption and breast cancer recurrence and survival among women with early-stage breast cancer: the life after cancer epidemiology study. J Clin Oncol 2010; 28:4410.</a></li><li><a class="nounderline abstract_t">Gerber B, Scholz C, Reimer T, et al. Complementary and alternative therapeutic approaches in patients with early breast cancer: a systematic review. Breast Cancer Res Treat 2006; 95:199.</a></li><li><a class="nounderline abstract_t">Yao S, Kwan ML, Ergas IJ, et al. Association of Serum Level of Vitamin D at Diagnosis With Breast Cancer Survival: A Case-Cohort Analysis in the Pathways Study. JAMA Oncol 2017; 3:351.</a></li><li><a class="nounderline abstract_t">Lyman GH, Greenlee H, Bohlke K, et al. Integrative Therapies During and After Breast Cancer Treatment: ASCO Endorsement of the SIO Clinical Practice Guideline. J Clin Oncol 2018; 36:2647.</a></li><li><a class="nounderline abstract_t">Zick SM, Sen A, Wyatt GK, et al. Investigation of 2 Types of Self-administered Acupressure for Persistent Cancer-Related Fatigue in Breast Cancer Survivors. Lancet Oncol 2016; 11:1470.</a></li><li><a class="nounderline abstract_t">Hershman DL, Unger JM, Greenlee H, et al. Effect of Acupuncture vs Sham Acupuncture or Waitlist Control on Joint Pain Related to Aromatase Inhibitors Among Women With Early-Stage Breast Cancer: A Randomized Clinical Trial. JAMA 2018; 320:167.</a></li><li><a class="nounderline abstract_t">Lengacher CA, Reich RR, Paterson CL, et al. Examination of Broad Symptom Improvement Resulting From Mindfulness-Based Stress Reduction in Breast Cancer Survivors: A Randomized Controlled Trial. J Clin Oncol 2016; 34:2827.</a></li><li><a class="nounderline abstract_t">Bower JE, Crosswell AD, Stanton AL, et al. Mindfulness meditation for younger breast cancer survivors: a randomized controlled trial. Cancer 2015; 121:1231.</a></li><li><a class="nounderline abstract_t">Schell LK, Monsef I, Wöckel A, Skoetz N. Mindfulness-based stress reduction for women diagnosed with breast cancer. Cochrane Database Syst Rev 2019; 3:CD011518.</a></li><li><a class="nounderline abstract_t">Park S, Sato Y, Takita Y, et al. Mindfulness-Based Cognitive Therapy for Psychological Distress, Fear of Cancer Recurrence, Fatigue, Spiritual Well-Being, and Quality of Life in Patients With Breast Cancer-A Randomized Controlled Trial. J Pain Symptom Manage 2020; 60:381.</a></li><li><a class="nounderline abstract_t">Bower JE, Partridge AH, Wolff AC, et al. Targeting Depressive Symptoms in Younger Breast Cancer Survivors: The Pathways to Wellness Randomized Controlled Trial of Mindfulness Meditation and Survivorship Education. J Clin Oncol 2021; 39:3473.</a></li><li><a class="nounderline abstract_t">Hebert JR, Hurley TG, Ma Y. The effect of dietary exposures on recurrence and mortality in early stage breast cancer. Breast Cancer Res Treat 1998; 51:17.</a></li><li><a class="nounderline abstract_t">Saxe GA, Rock CL, Wicha MS, Schottenfeld D. Diet and risk for breast cancer recurrence and survival. Breast Cancer Res Treat 1999; 53:241.</a></li><li><a class="nounderline abstract_t">Flatt SW, Thomson CA, Gold EB, et al. Low to moderate alcohol intake is not associated with increased mortality after breast cancer. Cancer Epidemiol Biomarkers Prev 2010; 19:681.</a></li><li><a class="nounderline abstract_t">Woo JC, Yu T, Hurd TC. Breast cancer in pregnancy: a literature review. Arch Surg 2003; 138:91.</a></li><li><a class="nounderline abstract_t">Largillier R, Savignoni A, Gligorov J, et al. Prognostic role of pregnancy occurring before or after treatment of early breast cancer patients aged &lt;35 years: a GET(N)A Working Group analysis. Cancer 2009; 115:5155.</a></li><li><a class="nounderline abstract_t">Helewa M, Lévesque P, Provencher D, et al. Breast cancer, pregnancy, and breastfeeding. J Obstet Gynaecol Can 2002; 24:164.</a></li><li><a class="nounderline abstract_t">Iqbal J, Amir E, Rochon PA, et al. Association of the Timing of Pregnancy With Survival in Women With Breast Cancer. JAMA Oncol 2017; 3:659.</a></li><li><a class="nounderline abstract_t">Azim Jr H, Kroman N, Ameye L, et al. Pregnancy following estrogen receptor-positive breast cancer is safe – Results from a large multi-center case-control study. Eur J Cancer 2012; 48S: European Breast Cancer Conference #21.</a></li><li><a class="nounderline abstract_t">Valachis A, Tsali L, Pesce LL, et al. Safety of pregnancy after primary breast carcinoma in young women: a meta-analysis to overcome bias of healthy mother effect studies. Obstet Gynecol Surv 2010; 65:786.</a></li><li><a class="nounderline abstract_t">Partridge AH, Niman SM, Ruggeri M, et al. Interrupting Endocrine Therapy to Attempt Pregnancy after Breast Cancer. N Engl J Med 2023; 388:1645.</a></li><li><a class="nounderline abstract_t">Sutton R, Buzdar AU, Hortobagyi GN. Pregnancy and offspring after adjuvant chemotherapy in breast cancer patients. Cancer 1990; 65:847.</a></li><li><a class="nounderline abstract_t">Azim HA Jr, Santoro L, Pavlidis N, et al. Safety of pregnancy following breast cancer diagnosis: a meta-analysis of 14 studies. Eur J Cancer 2011; 47:74.</a></li><li><a class="nounderline abstract_t">Calhoun K, Hansen N. The effect of pregnancy on survival in women with a history of breast cancer. Breast Dis 2005-2006; 23:81.</a></li><li><a class="nounderline abstract_t">Azim HA Jr, Kroman N, Paesmans M, et al. Prognostic impact of pregnancy after breast cancer according to estrogen receptor status: a multicenter retrospective study. J Clin Oncol 2013; 31:73.</a></li><li><a class="nounderline abstract_t">Lambertini M, Kroman N, Ameye L, et al. Long-term Safety of Pregnancy Following Breast Cancer According to Estrogen Receptor Status. J Natl Cancer Inst 2018; 110:426.</a></li><li><a class="nounderline abstract_t">Lambertini M, Blondeaux E, Bruzzone M, et al. Pregnancy After Breast Cancer: A Systematic Review and Meta-Analysis. J Clin Oncol 2021; 39:3293.</a></li><li><a class="nounderline abstract_t">Lambertini M, Ameye L, Hamy AS, et al. Pregnancy After Breast Cancer in Patients With Germline BRCA Mutations. J Clin Oncol 2020; 38:3012.</a></li><li><a class="nounderline abstract_t">Lambertini M, Blondeaux E, Agostinetto E, et al. Pregnancy After Breast Cancer in Young BRCA Carriers: An International Hospital-Based Cohort Study. JAMA 2024; 331:49.</a></li><li><a class="nounderline abstract_t">Trinh XB, Tjalma WA, Makar AP, et al. Use of the levonorgestrel-releasing intrauterine system in breast cancer patients. Fertil Steril 2008; 90:17.</a></li><li><a class="nounderline abstract_t">Vaz-Luis I, Partridge AH. Exogenous reproductive hormone use in breast cancer survivors and previvors. Nat Rev Clin Oncol 2018; 15:249.</a></li><li><a class="nounderline abstract_t">Kwan ML, Cheng RK, Iribarren C, et al. Risk of Cardiometabolic Risk Factors in Women With and Without a History of Breast Cancer: The Pathways Heart Study. J Clin Oncol 2022; 40:1635.</a></li><li><a class="nounderline abstract_t">Greenlee H, Iribarren C, Rana JS, et al. Risk of Cardiovascular Disease in Women With and Without Breast Cancer: The Pathways Heart Study. J Clin Oncol 2022; 40:1647.</a></li><li><a class="nounderline abstract_t">Hsu T, Ennis M, Hood N, et al. Quality of life in long-term breast cancer survivors. J Clin Oncol 2013; 31:3540.</a></li><li><a class="nounderline abstract_t">Ganz PA, Kwan L, Stanton AL, et al. Quality of life at the end of primary treatment of breast cancer: first results from the moving beyond cancer randomized trial. J Natl Cancer Inst 2004; 96:376.</a></li><li><a class="nounderline abstract_t">Kroenke CH, Rosner B, Chen WY, et al. Functional impact of breast cancer by age at diagnosis. J Clin Oncol 2004; 22:1849.</a></li></ol></div><div id="topicVersionRevision">Topic 15781 Version 79.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="http://gco.iarc.fr/today/data/factsheets/populations/900-world-fact-sheets.pdf" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : World Health Organization International Agency for Research on Cancer. The Global Cancer Observatory. 2018 statistics. Available at: http://gco.iarc.fr/today/data/factsheets/populations/900-world-fact-sheets.pdf (Accessed on January 17, 2019).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36633525" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Cancer statistics, 2023.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29313949" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Cancer statistics, 2018.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19332716" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Comparisons of patient and physician expectations for cancer survivorship care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19332716" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Comparisons of patient and physician expectations for cancer survivorship care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19332716" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Comparisons of patient and physician expectations for cancer survivorship care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35736631" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Cancer treatment and survivorship statistics, 2022.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23129741" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Breast cancer follow-up and management after primary treatment: American Society of Clinical Oncology clinical practice guideline update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15459225" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Effectiveness of routine visits and routine tests in detecting isolated locoregional recurrences after treatment for early-stage invasive breast cancer: a meta-analysis and systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18000508" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Follow-up in breast cancer: does routine clinical examination improve outcome? A systematic review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21130643" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : The value of routine physical examination in the follow up of women with a history of early breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26644543" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17486134" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Alternative methods of follow up in breast cancer: a systematic review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1985723" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Postoperative follow-up of patients with early breast cancer. Patterns of care among clinical oncologists and a review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7842569" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Follow-up of patients with breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10551200" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Preventive health care, 1999 update: 3. Follow-up after breast cancer. Canadian Task Force on Preventive Health Care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18187486" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Breast conservation therapy for stage I or stage II breast cancer: a meta-analysis of randomized controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14965672" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Surveillance mammography after treatment of primary breast cancer: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17548838" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Mammography surveillance and mortality in older breast cancer survivors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17548838" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Mammography surveillance and mortality in older breast cancer survivors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17957465" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Surveillance mammography and the risk of death among elderly breast cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16409580" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Reduced mortality rate associated with annual mammograms after breast cancer therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8511295" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Breast cancer recurrence after lumpectomy and radiation therapy for early-stage disease: prognostic significance of detection method.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8418240" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Prognosis following salvage mastectomy for recurrence in the breast after conservative surgery and radiation therapy for early-stage breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17533401" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Changing pattern of the detection of locoregional relapse in breast cancer: the Edinburgh experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21343578" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Accuracy and outcomes of screening mammography in women with a personal history of early-stage breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1848469" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : The contribution of routine follow-up mammography to an early detection of asynchronous contralateral breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/943222" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Cancer of the remaining breast: radiologic contribution to diagnosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3942996" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Has monitoring of the contralateral breast improved the prognosis in patients treated for primary breast cancer?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17392385" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26641959" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37150275" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Breast Cancer Screening for Women at Higher-Than-Average Risk: Updated Recommendations From the ACR.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37150275" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Breast Cancer Screening for Women at Higher-Than-Average Risk: Updated Recommendations From the ACR.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22476755" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Use of magnetic resonance imaging in detection of breast cancer recurrence: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36454573" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Yield of Surveillance Imaging After Mastectomy With or Without Reconstruction for Patients With Prior Breast Cancer: A Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22474203" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Detection of breast cancer with addition of annual screening ultrasound or a single screening MRI to mammography in women with elevated breast cancer risk.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17898585" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Surveillance mammography following the treatment of primary breast cancer with breast reconstruction: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17898585" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Surveillance mammography following the treatment of primary breast cancer with breast reconstruction: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17898585" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Surveillance mammography following the treatment of primary breast cancer with breast reconstruction: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27892991" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Surveillance Mammography in Older Patients With Breast Cancer-Can We Ever Stop?: A Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19093701" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Aromatase inhibitor-associated bone loss: clinical considerations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15674884" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Follow-up strategies for women treated for early breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24627271" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Promoting quality and evidence-based care in early-stage breast cancer follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6388726" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Detection of liver metastases. A prospective study comparing liver enzymes, scintigraphy, ultrasonography and computed tomography.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7055392" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : A prospective analysis of laboratory tests and imaging studies to detect hepatic lesions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/626572" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : An assessment of routine liver scanning in patients with breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9196146" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Use of Truquant BR radioimmunoassay for early detection of breast cancer recurrence in patients with stage II and stage III disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7579505" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Use of serial carcinoembryonic antigen and CA 15.3 assays in detecting relapses in breast cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7652494" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Breast cancer and clinical utility of CA 15-3 and CEA.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12044504" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Ca 15-3 in the follow-up of localised breast cancer: a prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12870135" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : The follow-up of breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17116247" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Intensive post-operative follow-up of breast cancer patients with tumour markers: CEA, TPA or CA15.3 vs MCA and MCA-CA15.3 vs CEA-TPA-CA15.3 panel in the early detection of distant metastases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12691319" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : The contribution of the CEA marker to CA 15.3 in the follow-up of breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11489813" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : A re-evaluation of carcinoembryonic antigen (CEA) as a serum marker for breast cancer: a prospective longitudinal study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17954709" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14619990" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Screening chest imaging studies are not effective in the follow-up of breast cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14531495" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Role of chest X-ray in diagnosis of the first breast cancer relapse: a randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11172954" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Unsuspected abnormalities noted on CT treatment-planning scans obtained for breast and chest wall irradiation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2702456" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Follow-up after treatment of primary breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8098950" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Follow-up of breast cancer patients stage I-II: a baseline strategy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3806160" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Screening for recurrent breast cancer--its effectiveness and prognostic value.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6518296" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : The efficacy of bone scanning in the follow-up of patients with operable breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3485185" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : First repeated bone scan in the observation of patients with operable breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21887484" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Diagnosis of bone metastases: a meta-analysis comparing¹⁸FDG PET, CT, MRI and bone scintigraphy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8182811" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Impact of follow-up testing on survival and health-related quality of life in breast cancer patients. A multicenter randomized controlled trial. The GIVIO Investigators.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11373208" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Breast cancer: assessing the use of routine pelvic CT in patient evaluation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8055979" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Value of routine abdominal and lymph node sonography in the follow-up of breast cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11884491" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Whole-body (18)F-FDG PET and conventional imaging for predicting outcome in previously treated breast cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12712329" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : [18F]-Fluorodeoxyglucose positron emission tomography in patients with suspected recurrence of breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15803356" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : A meta-analysis of FDG-PET for the evaluation of breast cancer recurrence and metastases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32170028" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35658506" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Circulating Tumor DNA and Late Recurrence in High-Risk Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31369045" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Assessment of Molecular Relapse Detection in Early-Stage Breast Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19123472" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Prospective cohort study of lifetime physical activity and breast cancer survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18250341" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Physical activity and survival after diagnosis of invasive breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11844838" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Weight loss in breast cancer patient management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20805458" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Alcohol consumption and breast cancer recurrence and survival among women with early-stage breast cancer: the life after cancer epidemiology study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16254687" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Complementary and alternative therapeutic approaches in patients with early breast cancer: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27832250" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Association of Serum Level of Vitamin D at Diagnosis With Breast Cancer Survival: A Case-Cohort Analysis in the Pathways Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29889605" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Integrative Therapies During and After Breast Cancer Treatment: ASCO Endorsement of the SIO Clinical Practice Guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Investigation of 2 Types of Self-administered Acupressure for Persistent Cancer-Related Fatigue in Breast Cancer Survivors</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29998338" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Effect of Acupuncture vs Sham Acupuncture or Waitlist Control on Joint Pain Related to Aromatase Inhibitors Among Women With Early-Stage Breast Cancer: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27247219" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Examination of Broad Symptom Improvement Resulting From Mindfulness-Based Stress Reduction in Breast Cancer Survivors: A Randomized Controlled Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25537522" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Mindfulness meditation for younger breast cancer survivors: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30916356" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Mindfulness-based stress reduction for women diagnosed with breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32105790" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Mindfulness-Based Cognitive Therapy for Psychological Distress, Fear of Cancer Recurrence, Fatigue, Spiritual Well-Being, and Quality of Life in Patients With Breast Cancer-A Randomized Controlled Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34406839" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Targeting Depressive Symptoms in Younger Breast Cancer Survivors: The Pathways to Wellness Randomized Controlled Trial of Mindfulness Meditation and Survivorship Education.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9877026" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : The effect of dietary exposures on recurrence and mortality in early stage breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10369070" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Diet and risk for breast cancer recurrence and survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20160253" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Low to moderate alcohol intake is not associated with increased mortality after breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12511159" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Breast cancer in pregnancy: a literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19691088" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Prognostic role of pregnancy occurring before or after treatment of early breast cancer patients aged&lt;35 years: a GET(N)A Working Group analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12196882" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Breast cancer, pregnancy, and breastfeeding.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28278319" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Association of the Timing of Pregnancy With Survival in Women With Breast Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Pregnancy following estrogen receptor-positive breast cancer is safe–Results from a large multi-center case-control study</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21411023" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Safety of pregnancy after primary breast carcinoma in young women: a meta-analysis to overcome bias of healthy mother effect studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37133584" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Interrupting Endocrine Therapy to Attempt Pregnancy after Breast Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2297653" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Pregnancy and offspring after adjuvant chemotherapy in breast cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20943370" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Safety of pregnancy following breast cancer diagnosis: a meta-analysis of 14 studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16823170" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : The effect of pregnancy on survival in women with a history of breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23169515" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Prognostic impact of pregnancy after breast cancer according to estrogen receptor status: a multicenter retrospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29087485" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Long-term Safety of Pregnancy Following Breast Cancer According to Estrogen Receptor Status.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34197218" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Pregnancy After Breast Cancer: A Systematic Review and Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32673153" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Pregnancy After Breast Cancer in Patients With Germline BRCA Mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/38059899" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Pregnancy After Breast Cancer in Young BRCA Carriers: An International Hospital-Based Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17706209" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Use of the levonorgestrel-releasing intrauterine system in breast cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29358778" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Exogenous reproductive hormone use in breast cancer survivors and previvors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35025627" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Risk of Cardiometabolic Risk Factors in Women With and Without a History of Breast Cancer: The Pathways Heart Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35385342" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Risk of Cardiovascular Disease in Women With and Without Breast Cancer: The Pathways Heart Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23980087" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Quality of life in long-term breast cancer survivors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14996859" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Quality of life at the end of primary treatment of breast cancer: first results from the moving beyond cancer randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15143077" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Functional impact of breast cancer by age at diagnosis.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
